Patient and transplantation characteristics
Characteristic . | Number . |
|---|---|
| No. of patients | 42 |
| Age, y, range (median) | 12-65 (52) |
| Sex, M/F | 27/15 |
| CMV status | |
| R+/D+ | 12 |
| R+/D- | 10 |
| R-/D+ | 6 |
| R-/D- | 14 |
| Time to transplantation, mo, range (median) | 3-112 (9) |
| No. of prior therapies, n = 22, range (median) | 1-6 (2) |
| Disease | |
| CML | 4 |
| BP | 2 |
| BP in remission | 2 |
| MDS | 38 |
| FAB | |
| RA high-risk | 6 |
| RAEB | 11 |
| RAEB-t | 4 |
| Cytogenetic risk* | |
| Good | 6 |
| Intermediate | 4 |
| Poor | 11 |
| IPSS* | |
| Low | 0 |
| Intermediate-1 | 7 |
| Intermediate-2 | 10 |
| High | 4 |
| AML after MDS or CMML | 12 |
| Untreated | 2 |
| CR | 5 |
| Resistant | 5 |
| BM blasts,† %, range (median) | 0-82 (6.5) |
| PB blasts,† %, range (median) | 0-26 (0) |
| CMML | 5 |
| PBSC donor | |
| HLA-matched related | 16 |
| Unrelated | |
| HLA-A, B, C, DRB1, and DQB1 matched | 15 |
| A, B, or C mismatch | 7 |
| DRB1 mismatch | 4 |
| PBSC dose | |
| CD34+ cells, × 106/kg, median (range) | 7.48 (1.3-25.4) |
| CD3+ cells, × 108/kg, median (range) | 3.2 (1.3-6.2) |
Characteristic . | Number . |
|---|---|
| No. of patients | 42 |
| Age, y, range (median) | 12-65 (52) |
| Sex, M/F | 27/15 |
| CMV status | |
| R+/D+ | 12 |
| R+/D- | 10 |
| R-/D+ | 6 |
| R-/D- | 14 |
| Time to transplantation, mo, range (median) | 3-112 (9) |
| No. of prior therapies, n = 22, range (median) | 1-6 (2) |
| Disease | |
| CML | 4 |
| BP | 2 |
| BP in remission | 2 |
| MDS | 38 |
| FAB | |
| RA high-risk | 6 |
| RAEB | 11 |
| RAEB-t | 4 |
| Cytogenetic risk* | |
| Good | 6 |
| Intermediate | 4 |
| Poor | 11 |
| IPSS* | |
| Low | 0 |
| Intermediate-1 | 7 |
| Intermediate-2 | 10 |
| High | 4 |
| AML after MDS or CMML | 12 |
| Untreated | 2 |
| CR | 5 |
| Resistant | 5 |
| BM blasts,† %, range (median) | 0-82 (6.5) |
| PB blasts,† %, range (median) | 0-26 (0) |
| CMML | 5 |
| PBSC donor | |
| HLA-matched related | 16 |
| Unrelated | |
| HLA-A, B, C, DRB1, and DQB1 matched | 15 |
| A, B, or C mismatch | 7 |
| DRB1 mismatch | 4 |
| PBSC dose | |
| CD34+ cells, × 106/kg, median (range) | 7.48 (1.3-25.4) |
| CD3+ cells, × 108/kg, median (range) | 3.2 (1.3-6.2) |
CMV indicates cytomegalovirus; R, recipient; +, seropositive; D, donor; -, seronegative; CML, chronic myelogenous leukemia; BP, blast phase; MDS, myelodysplastic syndrome; FAB, French-American-British classification; RA, refractory anemia; RAEB, refractory anemia with excess of blasts; AML, acute myelogenous leukemia; CMML, chronic myelomonocytic leukemia; CR, complete remission; BM, bone marrow; PB, peripheral blood; and PBSC, peripheral blood stem cell
Relates to MDS only and was scored according to International Prognostic Scoring System15
Relates to AML only